Ablexis Announces Perpetual License Of The Alivamab Mouse To A Top 15 Pharm

AlivaMab Mouse Emerging as Top Pharmas’ Next-Generation Antibody Drug Discovery Platform of Choice

BURLINGAME, Calif.--(BUSINESS WIRE)--2, 2016 – Ablexis, LLC announced today the expansion of the roster of licensees of its AlivaMab Mouse technology to include an additional top 15 pharmaceutical company. The AlivaMab Mouse is a unique, next-generation transgenic mouse platform for human therapeutic antibody discovery. This perpetual, non-exclusive license provides the licensee with its own colony of AlivaMab Mouse and broad rights to use the AlivaMab Mouse for antibody drug discovery and development. Ablexis will receive an eight-figure up-front payment.

“An additional top-tier pharmaceutical company has chosen to license and internalize the AlivaMab Mouse, which is particularly gratifying in light of the availability of several other therapeutic antibody discovery technologies, including other transgenic rodents, in vitro display technologies and humanization”

Multiple top pharmaceutical companies have now implemented the AlivaMab Mouse into their in-house antibody drug discovery processes since announcement of its availability in December 2014. Ablexis and its licensees have demonstrated repeatedly that the AlivaMab Mouse is a robust technology for efficiently generating sequence and epitope diverse panels of high affinity and high potency monoclonal antibodies against broad classes of human therapeutic targets, including membrane multispanning targets such as G protein-coupled receptors (GPCRs).

“An additional top-tier pharmaceutical company has chosen to license and internalize the AlivaMab Mouse, which is particularly gratifying in light of the availability of several other therapeutic antibody discovery technologies, including other transgenic rodents, in vitro display technologies and humanization,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “Some of the most experienced companies in antibody drug discovery and development have validated that our careful design of the AlivaMab Mouse yields real advantages, including antibody diversity and quality, ease of use, broad applicability and freedom to operate. Ablexis expects ongoing expansion of its roster of licensees of the AlivaMab Mouse technology for the discovery of the next generation of human therapeutic antibodies.”

About Ablexis, LLC

Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique next-generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has announced non-exclusive licensing of the AlivaMab Mouse technology to multiple top global pharmaceutical companies and continues making the AlivaMab Mouse available via non-exclusive licenses. The company was founded in 2009 and is based in Burlingame, California; more information can be found by visiting the company’s website at www.ablexis.com.